Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;96(3):321-9.
doi: 10.1007/s11060-009-9967-4. Epub 2009 Jul 31.

Different molecular patterns in glioblastoma multiforme subtypes upon recurrence

Affiliations

Different molecular patterns in glioblastoma multiforme subtypes upon recurrence

Ramon Martinez et al. J Neurooncol. 2010 Feb.

Abstract

One of the hallmarks of glioblastoma is its inherent tendency to recur. At this point patients with relapsed GBM show a survival time of only few months. The molecular basis of the recurrence process in GBM is still poorly understood. The aim of the present study was to investigate the genetic profile of relapsed GBM compared to their respective primary tumors. We have included 20 paired GBMs. In all tumor samples, we have analyzed p53 and PTEN status by sequencing analysis, EGFR amplification by semiquantitative PCR and a wide-genome fingerprinting was performed by microsatellite analysis. Among primary GBM, we observed twelve type 2 GBM, four type 1 GBM and four further GBM showing neither p53 mutations nor EGFR amplification (non-type 1-non-type 2 GBM). Upon recurrence, we have detected two molecular patterns of tumor progression: GBM initially showing either type 1 or type 2 profiles conserved them at the time of relapse. In contrast, non-type 1-non-type 2 GBM acquired the typical pattern of type 2 GBM and harbor EGFR amplification without p53 mutation. New PTEN mutations upon relapse were only detected in type 2 GBM. Additional LOH were more frequently identified in relapses of type 2 GBM than in those showing the type 1 signature. Taken together, our results strongly suggest that recurrences of GBM may display two distinct pattern of accumulation of molecular alterations depending on the profile of the original tumor.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Upper row: wild type sequence of p53. Lower row: base exchange mutation (GGA→GTA) of p53 (exon 8, codon 266), predicting the aminoacid substitution Gly→Val. The arrow indicates the base exchange
Fig. 2
Fig. 2
Upper row: wild type sequence of PTEN. Lower row: base exchange mutation (CAT→AAT) of PTEN (exon 4, codon 75) predicting the aminoacid substitution His→Asn. The arrow indicates the base exchange
Fig. 3
Fig. 3
Graphic showing two molecular patterns of GBM recurrence

References

    1. Salcman M, Kaplan R. Intracranial tumors in adults. In: Salcman M, editor. Neurology of brain tumors. Baltimore: Williams & Wilkins; 1991. pp. 1339–1352.
    1. Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol. 2001;12:255–257. doi: 10.1023/A:1008336732273. - DOI - PubMed
    1. Stupp R, Dietrich PY, Ostermann-Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375–1382. doi: 10.1200/JCO.20.5.1375. - DOI - PubMed
    1. Walker MD, Green SB, Byar DP, Alexander E, Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Jr, Mealey J, Jr, Owens G, Ransohoff J, 2nd, Robertson JT, Shapiro WR, Smith KR, Jr, Wilson CB, Strike TA. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323–1329. - PubMed
    1. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29–38. doi: 10.1016/S1470-2045(07)70384-4. - DOI - PubMed